Zandelisib

Overview

Zandelisib (ME-401) is a selective, orally active, non-covalent inhibitor of PI3Kδ . Zandelisib can sustainably inhibit AKT phosphorylation and downstream signaling pathways. Zandelisib can be used in the study of malignancies such as relapsed/refractory B-cell lymphoma.

Application

Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt

Product Information

• Catalog No.: HY-109198
• CAS No.: 1401436-95-0
• Molecular Formula: C31H38F2N8O
• Molecular Weight: 576.68
• Purity: 99.67%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (4.34 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source